Drugs.com - Clinical Trials

Theravance Biopharma Presents Two New Ampreloxetine Analyses

DUBLIN, April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the...

Apr 8, 2025 - 03:58
 0
Theravance Biopharma Presents Two New Ampreloxetine Analyses
DUBLIN, April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the...
Read More

Tags:

Previous Article

Deep Yellow delays Tumas decision again amid 'broken' sector

Next Article

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alz...

Related Posts

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan ...

Mar 26, 2025  0

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Nurix Therapeutics Receives U.S. FDA Fast Track Designa...

Feb 9, 2025  0

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces U.S. FDA Breakthrough Therapy Des...

Feb 9, 2025  0